Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Ketamine as Adjunct to Antidepressant Therapy in Treatment-Resistant Depression
NCT05615948Phase 4Completed
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 4 trial of aspirin + ketamine in treatment-resistant depression (TRD). Started Dec 2022; status: completed.
02
Drugs
aspirin + ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05615948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615948.